
There’s more money sloshing around in biotech than ever before.
Over the past year, several trends have converged to create a historic financing environment for startups, full of what industry insiders call “dry powder.”
Experts say this kind of environment could be great for the industry as a whole, allowing startups to raise more money and move much faster. But venture capitalists also told STAT that increased interest in biopharma companies means competition for investment has become unusually fierce.